36 results about "Endothelial nitric oxide synthase" patented technology

A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to endothelial nitric oxide synthase (NO synthase), the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. A method of treating erectile dysfunctions and vegetative disturbances of male climax by regulating the level of cyclic guanosine monophosphate (cGMP) in the cavernous bodies on sexual stimulation, the method being characterized by the use of activated forms of ultra-low doses of antibodies to the entire molecule of the endothelial NO synthase or to its polypeptide fragments, activated forms being prepared by multiple consecutive dilutions and exposure to external factors.

The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an HMG-CoA reductase inhibitor, and a formulation comprising a precursor of NO, such as L-arginine, may be used to treat or prevent cerebrovascular and / or cardiovascular diseases or disorders.

This invention relates to transgenic non-human animals comprising a disrupted endothelial nitric oxide synthase gene. These animals exhibit abnormal wound-healing properties and hypertension. This invention also relates to methods of using the transgenic animals to screen for compounds having a potential therapeutic utility for vascular endothelial disorders, such as hypertension, cerebral ischemia or stroke, atherosclerosis and wound-healing activities. Moreover, this invention also relates to methods of treating a patient suffering from hypertension and wound-healing abnormalities with the compounds identified using the transgenic animals, and methods of making the transgenic animals. A method of treating a wound using nitroglycerin is also provided.

The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an HMG-CoA reductase inhibitor, and a formulation comprising a precursor of NO, such as L-arginine, may be used to treat or prevent cerebrovascular and / or cardiovascular diseases or disorders.

A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to endothelial nitric oxide synthase (NO synthase), the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. A method of treating erectile dysfunctions and vegetative disturbances of male climax by regulating the level of cyclic guanosine monophosphate (cGMP) in the cavernous bodies on sexual stimulation, the method being characterized by the use of activated forms of ultra-low doses of antibodies to the entire molecule of the endothelial NO synthase or to its polypeptide fragments, activated forms being prepared by multiple consecutive dilutions and exposure to external factors.

Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sF1t-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.

The present invention provides methods for increasing peroxisome proliferator-activated receptor-gamma (PPARγ) activity and / or endothelial nitric oxide synthase (eNOS) activity in a subject by administering to the subject a plant extract or plant juice from thyme, oregano, clove, nutmeg, red clover, bay leaves, red onion or grapes.

The present invention discloses methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin, endothelial nitric oxide synthase, PGI2, TGF-betal, TGF-beta3, activin A, BMP2, BMP7, and sFlt-1 expression levels or biological activity. Also disclosed are methods of diagnosing a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, that include the measurement of any one or more of the following: soluble endoglin, endothelial nitric oxide synthase, PGI2, TGF-betal, TGF-beta3, activin A, BMP2, BMP7, and sFlt-1 expression levels or biological activity.

The invention provides a pharmaceutical composition comprising as an active ingredient a pharmaceutical agent comprising a DNA sequence that codes for a protein which possesses the biological activity of inducible nitrogen monoxide synthase (iNOS) and eukaryotic regulation elements, wherein the eukaryotic regulation elements result in the expression of said DNA sequence in eukaryotic cells, and a pharmaceutically acceptable carrier. The pharmaceutical agent can be complexed to liposomes.

Compositions, prodrugs and methods for inhibiting neural Nitric Oxide Synthase (nNOS). By inhibiting nNOS, the compounds, prodrugs and methods of the presnet invention are useable to treat or prevent disorders in human or veterinary patients that are caused, mediated or agrevated by Nitric Oxide within the body.

The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an HMG-CoA reductase inhibitor, and a formulation comprising a precursor of NO, such as L-arginine, may be used to treat or prevent cerebrovascular and / or cardiovascular diseases or disorders.

The invention discloses a kit that is used for genetic risk detection of individual angiocardiopathy as well as health evaluation and management. The kit comprises an electrophoresis detecting primer pair that is used for detecting rs4646994 SNP polymorphism genotype on the gene of angiotonin converting enzyme (ACE), particularity primer pairs and particularity fluorescent probe pairs that are used for detecting rs5186 SNP locus on the gene of angiotonin II-1 type receptor (AGTR1), rs5443 SNP locus on the gene of G protein 3 subunit (GNB3) and rs1799983 SNP locus on the gene of endothelial nitric oxide synthase (NOS3), a fluorescent quantitative PCR routine component, and a PCR reaction component, etc. The kit of the invention implements cardiovascular health evaluation of detected person by evaluating the generic risk of developing angiocardiopathy and makes a health management plan that satisfies the genetic predisposition of detected person according to the four SNP locus genotypes that related with the genetic risk of developing angiocardiopathy of the detected person.

The present invention relates to a process for screening for a gene involving a coronary artery spasm-associated disease, which comprises detecting the presence of the relevant nucleotide substituents in the endothelial nitric oxide synthase (eNOS) gene. The present invention provides the ready diagnosis of a coronary artery spasm-associated disease such as angina, which cannot be conveniently screened by the conventional methods.

The invention discloses a method for early detection on the toxicity of the Paralytic shellfish poisoning toxin in the technical field of the biological engineering, which is to make the check solution by the on-site shellfishes and make the abdominal cavity injection to the mouse with the check solution to test the content of the acetylcholine in the mouse brain and the change on activity of the endothelial nitric oxide synthase. The Paralytic shellfish poisoning toxin can be gained from the content of the acetylcholine and activity of the endothelial nitric oxide synthase, which can make an early detection on the toxicity of the Paralytic shellfish poisoning toxin. The invention realizes the on-site and fast test and analysis to large amount of samples and the early detection on the toxicity, which reduces the time by two to ten times compared with the common mice method currently used in China, avoiding any occurrence of the individual symptom and applicable to the on-site and fast test and analysis to large amount of samples and the early detection on the toxicity. The invention is simple and convenient to operate with only test on change of common biochemical parameters required, which is applicable to promotion and use by the on-site and grass-root test departments.

The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based at least in part on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an HMG-CoA reductase inhibitor, and a formulation comprising a NO precursor, such as L-arginine The formulations are useful for treating or preventing cerebrovascular and / or cardiovascular diseases or disorders.

The invention provides aporphine and oxoaporphine compounds that have endothelial nitric oxide synthase (eNOS) maintaining or enhancing activities and may be used to manufacture a medicaments for preventing or treating ischemic diseases in human and mammal, and the ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc.

The present invention relates to a composition comprising a protein phosphatase 1 inhibitory peptide for treating vascular diseases. The composition of the present invention inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation to suppress abnormal proliferation of vascular smooth muscle cells (VSMCs), and activates eNOS of vascular endothelial cells (VECs) to induce the recovery from dysfunction, and thus can be favorably used in the treatment of vascular diseases including pulmonary hypertension.

The invention discloses a formula of a cosmetic. The cosmetic is prepared from the following components: 1-3 parts of dipropylene glycol, 2.5-3 parts of soybean isoflavone, 0.5-1 part of polyethyleneglycol-4, 1-2 parts of butanediol, 0.1-50 parts of L-arginine, 0.8-1.2 parts of sodium hyaluronate, 2-5 parts of glycerol, 3-5 parts of oligopeptide-1, 0.5-1 part of a snow lotus herb extract, 2 partsof phenoxyethanol, 0.5-1 part of a tea extract, 0.8-1.5 parts of dipotassium glycyrrhizinate, 0.2-1 part of trehalose, 0.3-1 part of xanthan gum, 1-1.5 parts of hydroxyethyl cellulose, 0.1-30 parts of menthol, 0.5-0.8 part of chlorphenesin and the balance of pure water. By adopting the scheme, the prepared cosmetic is absorbed by the skin by means of massage, produces L-citrulline subcutaneouslyby means of endothelial nitric oxide synthase, and releases nitrogen monoxide, thus having functions of increasing the blood flow of capillaries, promoting collagen synthesis, improving skin quality,promoting tissue regeneration and epithelial tissue healing, enhancing anti-inflammatory capacity and immunity, and the like. In addition, the cosmetic also can relieve the damage to skin mucous membrane and the itching allergy, and promote the healing of erosion and ulcer.

The invention relates to the technical field of medical equipment, and particularly relates to a regulation and control device for eNOS (Endothelial nitric oxide synthase) expression and activation. The regulation and control device disclosed by the invention for eNOS (Endothelial nitric oxide synthase) expression and activation comprises an ultrasonic irradiation component which irradiates ultrasonic waves to a subject. The regulation and control device, the treatment device and a treatment method disclosed by the invention are not only low in treatment expenditure, but also ensure the safety. In addition, the stability is high, and up-regulation of eNOS expression and activation in a living body can be effectively promoted, so that peripheral arterial diseases are treated effectively.

Compounds and related methods for selective inhibition of neuronal nitric oxide synthase over inducible and endothelial isoforms, such compounds as can provide reduced cationic character and enhanced bioavailability.

The invention discloses application of Pin1 siRNA in preparation of a targeted medicine for treating the alcoholic cardiomyopathy, and belongs to the field of prevention and treatment of the alcoholic cardiomyopathy. It is proved through experiments that Pin1 takes participate in the cardiac muscle cell apoptosis process caused by alcohol and high-dosage alcohol stimulates the expression and activity of Pin1. By means of Pin1 gene knock-out mediated by Pin1 siRNA, cardiac muscle cell apoptosis mediated by alcohol can be remarkably restrained; due to the over-expression of Pin1, the number of apoptosis muscle cells is further increased. It is further proved that Pin1 promotes mitochondria oxidative stress mediated by alcohol and restrains the expression of endothelial nitric oxide synthase. Through Pin1 gene knock-out mediated by Pin1 siRNA, mitochondria oxidative stress mediated by alcohol, the production decrease of NO and the level decrease of eNOS can be remarkably restrained, and therefore the occurrence and development process of the alcoholic cardiomyopathy is further delayed. An effective technological means is put forward to prevent and treat the alcoholic cardiomyopathy.

The invention discloses a human intron derived 27 base microRNA and an application thereof to blood pressure regulation. The human intron derived 27 base microRNA is generated by four-time duplicationof a fourth intron 27 base duplicon of eNOS (endothelial nitric oxide synthase), and the nucleotide sequence of the human intron derived 27 base microRNA is as shown in SEQ ID NO. 1. A high-expression plasmid is prepared according to the sequence, the high-expression plasmid and lipidosome are mixed according to the weight ratio of 3:1 and diluted by normal saline, and mixture is injected into the body of an SD (sprague-daw) rat through rat caudal veins to prove that the human intron derived 27 base microRNA has a regulating effect on rat blood pressure, can be used for researching hypertension diseases, finally can be used for screening some antihypertensive drugs and preparing a hypertension early warning chip and has a potential application prospect.

The present invention relates to methods of treatment and or prevention of vascular disease. The present invention also relates to a medical device for implantation in a patient undergoing vasculature therapy, the device comprising a therapeutic amount of FXYD1 or a derivative thereof capable of interaction with endothelial nitric oxide synthase. The present invention also relates to the use of FXYD1 and derivatives and variants thereof capable of interaction with endothelial nitric oxide synthase for the treatment or prevention of vascular disease.

The invention provides urechis unicinctus polypeptide with angiotensin converting enzyme inhibitory activity and application thereof. The urechis unicinctus polypeptide comprises a first polypeptide and / or a second polypeptide, wherein the amino acid sequence of the first polypeptide is as shown in SEQ ID NO. 1; and the amino acid sequence of the second polypeptide is as shown in SEQ ID NO. 2. Theurechis unicinctus polypeptide F2 and the urechis unicinctus polypeptide F7 have no inhibiting effect on proliferation of HUVEC cells, can antagonize the effect of noradrenaline (NE) on inhibiting NOrelease in the cells, and can inhibit the effect of promoting cell release ET-1 caused by the NE, so that the purpose of reducing blood pressure is achieved. According to the urechis unicinctus polypeptide, the activity of ACE is competitively inhibited, the content of bradykinin is increased, and the phosphorylation effect of endothelial nitric oxide synthase (eNOS) is influenced, so that the eNOS activity is improved, more NO is released, ET-1 is inhibited, and the effect of reducing blood pressure is achieved.